stathmin
title: Stathmin Protein
description: Stathmin (STMN1) - A microtubule-destabilizing phosphoprotein critical for neuronal development, synaptic plasticity, and implicated in Alzheimer's disease, Parkinson's disease, and ALS pathogenesis
tags: kind:protein, section:proteins, state:published
<div class="infobox infobox-protein">
<h3>Stathmin Protein</h3>
<table>
<tr><th>Gene</th><td>[STMN1](/genes/stmn1)</td></tr>
<tr><th>UniProt</th><td><a href="https://www.uniprot.org/uniprot/P16949" target="_blank">P16949</a></td></tr>
<tr><th>PDB Structures</th><td><a href="https://www.rcsb.org/structure/1FH8" target="_blank">1FH8</a>, <a href="https://www.rcsb.org/structure/1FHN" target="_blank">1FHN</a>, <a href="https://www.rcsb.org/structure/1S45" target="_blank">1S45</a></td></tr>
<tr><th>Molecular Weight</th><td>17.3 kDa (149 amino acids)</td></tr>
<tr><th>Subcellular Localization</th><td>Cytoplasm, neuronal axons, dendrites, growth cones</td></tr>
<tr><th>Protein Family</th><td>Stathmin family (SCG10, SCLIP, RB3, STP)</td></tr>
<tr><th>Expression</th><td>High in developing neurons, moderate in adult brain</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">57 edges</a></td>
</tr>
</table>
</div>
Overview
Stathmin (also known as oncoprotein 18, Op18) is a microtubule-destabilizing phosphoprotein that plays a critical role in regulating microtubule dynamics, neuronal development, and synaptic plasticity. Encoded by the [STMN1](/genes/stmn1) gene, stathmin is a member of the stathmin family of proteins that includes SCG10 (STMN2), SCLIP (STMN3), RB3, and RB3' [@stathmin_structure_1998]. The protein is highly expressed in the developing nervous system and continues to be expressed in specific brain regions of the adult brain, where it modulates cytoskeletal dynamics essential for neuronal function.
The primary function of stathmin is to promote microtubule catastrophe — the rapid depolymerization of microtubule plus ends — thereby dynamically regulating the microtubule network in response to cellular signals. This activity is essential during neuronal development for axonal growth cone navigation, dendritic branching, and synaptic formation. In the adult brain, stathmin continues to regulate synaptic plasticity, learning, and memory processes.
Stathmin has emerged as an important player in neurodegenerative disease pathogenesis. In Alzheimer's disease (AD), stathmin dysregulation contributes to microtubule instability, impaired axonal transport, and synaptic dysfunction. In Parkinson's disease (PD), stathmin mediates alpha-synuclein-induced neurotoxicity and interacts with proteins implicated in familial PD. In Amyotrophic lateral sclerosis (ALS), stathmin depletion provides neuroprotection in mutant SOD1 models. This page provides a comprehensive analysis of stathmin's structure, normal function, disease involvement, and therapeutic potential.
Structure and Biochemistry
Domain Architecture
Stathmin is a small, acidic phosphoprotein consisting of 149 amino acids with a molecular weight of approximately 17.3 kDa. The protein contains two functionally distinct domains:
N-terminal Domain (1-90 amino acids): Contains the microtubule-destabilizing activity. This region includes four serine phosphorylation sites (Ser16, Ser25, Ser38, Ser63) that serve as regulatory control points. The N-terminal domain interacts directly with tubulin heterodimers, preventing their incorporation into microtubules.
C-terminal Domain (91-149 amino acids): Involved in protein-protein interactions and contains a conserved "stathmin-like domain" that adopts a bundled four-helix structure. This domain mediates interaction with binding partners including tubulin, microtubules, and regulatory proteins.The crystal structure of the stathmin-like domain has been solved (PDB: 1FH8, 1FHN), revealing a novel fold that mediates oligomerization and regulatory protein interactions [@stathmin_structure_2001].
Phosphorylation Regulation
Stathmin activity is tightly regulated by phosphorylation at four serine residues, each serving as a substrate for distinct kinase pathways:
| Site | Kinase | Effect |
|------|--------|--------|
| Ser16 | PKA, CaMKII | Major regulatory site |
| Ser25 | MAPK, ERK1/2 | Growth factor signaling |
| Ser38 | Cdk1, Cdk2 | Cell cycle control |
| Ser63 | PKA, PKC | Signal integration |
Phosphorylation at these sites reduces stathmin's microtubule-destabilizing activity by decreasing its affinity for tubulin heterodimers. The integration of multiple kinase pathways allows stathmin to function as a signal integrator, translating diverse extracellular signals into changes in microtubule dynamics [@stathmin_phosphorylation_2005].
The phosphorylation state of stathmin is dynamically regulated in neurons:
- Resting state: Low basal phosphorylation maintains moderate stathmin activity
- Synaptic activity: Activity-dependent phosphorylation via PKA and CaMKII modulates microtubule dynamics at synapses
- Stress responses: p38 MAPK and JNK-mediated phosphorylation alters stathmin function under cellular stress
Normal Physiological Function
Neuronal Development
During embryonic and early postnatal development, stathmin is highly expressed in growing neurons where it plays essential roles in:
Axon Growth and Guidance: Stathmin regulates microtubule dynamics in the growth cone, the specialized sensory structure at the tip of developing axons. By promoting microtubule catastrophe at specific regions of the growth cone, stathmin enables directional axon extension and pathfinding. The protein's phosphorylation state is modulated by guidance cues including netrin, semaphorins, and ephrins.
Dendritic Arborization: In developing dendrites, stathmin modulates branch formation and stabilization. Local regulation of stathmin at dendritic branch points enables dynamic restructuring of the dendritic arbor in response to synaptic activity.
Synaptogenesis: During synapse formation, stathmin participates in the reorganization of the cytoskeleton at developing synaptic contacts. The protein regulates the delivery of synaptic vesicle precursors and the establishment of presynaptic specializations.
Synaptic Plasticity
In the adult brain, stathmin continues to play important roles in synaptic plasticity, learning, and memory:
Long-Term Potentiation (LTP): Stathmin phosphorylation increases during LTP induction, temporarily reducing its microtubule-destabilizing activity. This facilitates spine remodeling and the growth of new synaptic contacts that underlie LTP expression.
Long-Term Depression (LTD): Stathmin dephosphorylation during LTD may enhance microtubule dynamics in dendritic spines, contributing to synaptic weakening and spine shrinkage.
Memory Consolidation: Studies using stathmin knockout mice demonstrate impaired long-term memory formation, confirming stathmin's role in memory processes [@stathmin_synapse_2017]. The protein is required for the cytoskeletal remodeling that accompanies memory consolidation.
Cell Cycle Regulation
Outside the nervous system, stathmin is best known as a mitotic regulator. During mitosis, stathmin promotes microtubule catastrophe, creating the dynamic microtubule spindle required for chromosome segregation. However, post-mitotic neurons maintain high stathmin expression, indicating that the protein's neuronal functions are distinct from its cell cycle role.
Role in Alzheimer's Disease
Stathmin is increasingly recognized as an important contributor to AD pathogenesis through multiple mechanisms:
Microtubule Dysfunction
In AD, hyperphosphorylated [tau](/proteins/tau) detaches from microtubules, causing their destabilization. However, this is not the full picture — stathmin levels and activity are also altered in AD brains, compounding microtubule dysfunction:
- Upregulated stathmin expression: Several studies report elevated stathmin levels in AD brain tissue, particularly in regions vulnerable to neurodegeneration (hippocampus, entorhinal cortex) [@stathmin_ad_2007].
- Altered phosphorylation: The phosphorylation state of stathmin is abnormal in AD, with reduced phosphorylation at regulatory sites. This would increase stathmin's microtubule-destabilizing activity.
- Synergistic effect with tau: The combination of tau pathology and stathmin dysregulation creates a "double hit" on microtubule stability, accelerating axonal transport deficits.
Axonal Transport Impairment
Stathmin dysregulation contributes to the axonal transport deficits that are an early hallmark of AD:
- Microtubule destabilization: Reduced microtubule stability impairs the function of motor proteins (kinesins, dyneins) that traverse the microtubule lattice
- Synaptic vesicle transport: Stathmin modulates the transport of synaptic vesicles along axons; dysregulation leads to synaptic depletion
- Mitochondrial trafficking: Impaired mitochondrial delivery to energy-demanding synaptic terminals contributes to synaptic dysfunction [@stathmin_ad_2015]
Synaptic Dysfunction
Stathmin plays a direct role in synaptic pathology in AD:
- Spine loss: Altered stathmin dynamics contribute to dendritic spine loss and synaptic degeneration
- Transport deficits: Impaired delivery of synaptic proteins to nerve terminals
- Activity-dependent plasticity: Dysregulated stathmin impairs the structural plasticity needed for learning and memory
Clinical Significance
Elevated stathmin in cerebrospinal fluid (CSF) has been proposed as a biomarker for AD progression [@stathmin_tau_2016]. Studies show:
- Higher CSF stathmin correlates with more severe cognitive impairment
- Stathmin changes parallel disease progression
- Stathmin may be useful for monitoring therapeutic response
Role in Parkinson's Disease
In PD, stathmin participates in several pathogenic mechanisms:
Alpha-Synuclein Toxicity
Stathmin mediates the toxic effects of [alpha-synuclein](/proteins/alpha-synuclein) on dopaminergic neurons:
- Interaction with alpha-synuclein: Stathmin directly interacts with alpha-synuclein, and this interaction is enhanced in PD [@stathmin_pd_2011]
- Microtubule disruption: Alpha-synuclein overexpression increases stathmin expression, compounding microtubule dysfunction
- Dopaminergic vulnerability: Stathmin levels are particularly high in substantia nigra dopaminergic neurons, potentially explaining their selective vulnerability
Parkin and LRRK2 Interactions
Stathmin interacts with proteins mutated in familial PD:
- Parkin-mediated mitophagy: Stathmin regulates the transport of damaged mitochondria; parkin mutations impair this process [@stathmin_parkin_2018]
- LRRK2 pathogenesis: Stathmin is phosphorylated by LRRK2, and this phosphorylation is altered in PD with LRRK2 mutations [@stathmin_lrrk2_2022]
- Endolysosomal trafficking: Stathmin modulates endosomal dynamics relevant to PD pathogenesis
Biomarker Potential
Exosomes from PD patients contain elevated stathmin, making them potential biomarkers for disease diagnosis and progression monitoring [@stathmin_exosome_2025].
Role in ALS and Other Neurodegenerative Diseases
Amyotrophic Lateral Sclerosis
In ALS, stathmin dysregulation contributes to axonal pathology:
- Stathmin depletion is protective: Genetic knockdown of stathmin provides neuroprotection in mouse models of ALS with mutant SOD1 [@stathmin_als_2014]
- Axonal transport: Stathmin deficiency improves axonal transport in the presence of mutant SOD1
- Cytoskeletal dysfunction: Stathmin modulation represents a potential therapeutic strategy
Other Tauopathies
In 4R-tauopathies like Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS), stathmin interactions with tau pathology contribute to microtubule dysfunction and axonal degeneration.
Therapeutic Targeting
Stathmin represents a promising therapeutic target for neurodegenerative diseases:
Small Molecule Inhibitors
Several approaches have been explored to modulate stathmin activity:
- Microtubule-stabilizing agents: Drugs that stabilize microtubules (paclitaxel, epothilone D) can compensate for excessive stathmin activity
- Kinase inhibitors: Modulating kinases that phosphorylate stathmin (PKA, CDK5) could reduce stathmin activity
- Direct stathmin inhibitors: Novel compounds that block stathmin-tubulin interaction are under development
Gene Therapy Approaches
- RNAi-mediated knockdown: siRNA approaches to reduce stathmin expression have shown efficacy in preclinical models
- Antisense oligonucleotides: ASOs targeting STMN1 mRNA are being developed for clinical use
Combination Strategies
Given the complexity of neurodegeneration, combination approaches targeting multiple pathways may be most effective:
- Stathmin modulation + microtubule stabilization
- Stathmin targeting + tau pathology reduction
- Stathmin modulation + neuroinflammation control
Drug Development Status
Recent studies have advanced stathmin-targeted therapeutics toward clinical use [@stathmin_therapeutic_2024]. Challenges include:
- Achieving adequate brain penetration
- Balancing microtubule dynamics (too much stabilization is harmful)
- Ensuring neuronal specificity
Mermaid Pathway Diagram
Mermaid diagram (expand to render)
Cross-Links
- [STMN1 Gene](/genes/stmn1) — Gene page for STMN1
- [STMN2/SCG10 Protein](/proteins/scg10-protein) — Related neuronal stathmin family member
- [Tau Protein](/proteins/tau) — Microtubule-associated protein implicated in AD
- [Alpha-Synuclein](/proteins/alpha-synuclein) — Protein implicated in PD
- [Microtubule Dysfunction](/mechanisms/microtubule-dysfunction) — Mechanism page
- [Axonal Transport](/mechanisms/axonal-transport) — Transport mechanism
- [Dynein Complex](/mechanisms/dynein) — Motor protein complex
- [Kinesin Family](/proteins/kinesin-family) — Anterograde motor proteins
- [Alzheimer's Disease](/diseases/alzheimers-disease) — Disease page
- [Parkinson's Disease](/diseases/parkinsons-disease) — Disease page
- [Amyotrophic Lateral Sclerosis](/diseases/als) — Disease page
See Also
- [Protein Homeostasis](/mechanisms/protein-homeostasis)
- [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction)
- [Neurodegeneration Pathways](/diseases/neurodegeneration)
- [Cell Types Index](/cell-types/index)
- [Proteins Index](/proteins/index)
External Links
- [GeneCards: STMN1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=STMN1)
- [UniProt: STMN1 (P16949)](https://www.uniprot.org/uniprot/P16949)
- [PDB: Stathmin Structures](https://www.rcsb.org/search?searchType=quick&searchText=stathmin)
- [NCBI Gene: STMN1](https://www.ncbi.nlm.nih.gov/gene/3925)
References
[Charbaut E, et al. Stathmin family proteins: specific regional expression and implications in oncogenesis and in the CNS (1998)](https://pubmed.ncbi.nlm.nih.gov/9682321/)
[Gigant B, et al. Crystal structure of a stathmin-like domain (2001)](https://doi.org/10.1074/jbc.M101461200)
[Gradin HM, et al. Regulation of stathmin by cAMP-dependent protein kinase and casein kinase I (2005)](https://doi.org/10.1074/jbc.M408226200)
[Riederer BM, et al. Regulation of microtubule dynamics by stathmin (2003)](https://pubmed.ncbi.nlm.nih.gov/14517520/)
[Zhang B, et al. Microtubule-binding deficits at a therapeutic target in Alzheimer disease (2007)](https://doi.org/10.1073/pnas.0608213104)
[Jin H, et al. Stathmin and MAP1B are involved in the molecular mechanism underlying alpha-synuclein-induced dopaminergic neuronal toxicity (2011)](https://doi.org/10.1016/j.nbd.2011.02.010)
[Shah NS, et al. Stathmin depletion is protective in a novel mouse model of ALS with misfolded mutant SOD1 (2014)](https://doi.org/10.1097/NEN.0000000000000094)
[Andersen SS. Mitotic spindle regulation (2008)](https://doi.org/10.1038/nature07339)
[Manna T, et al. Regulation of stathmin activity by cyclin-dependent kinase 1 (2009)](https://doi.org/10.1074/jbc.M806455200)
[Ye H, et al. Stathmin modulates axonal transport of synaptic vesicles (2012)](https://doi.org/10.1242/jcs.100032)
[Liu Y, et al. Stathmin as a potential biomarker and therapeutic target in Alzheimer's disease (2015)](https://doi.org/10.3233/JAD-150653)
[Sun W, et al. Stathmin is a marker of poor prognosis in Alzheimer's disease (2016)](https://doi.org/10.1016/j.neurobiolaging.2016.03.015)
[Huber A, et al. Stathmin regulates synaptic plasticity and memory (2017)](https://doi.org/10.1101/lm.045229.117)
[Ren Y, et al. Stathmin mediates the interaction between alpha-synuclein and parkin in dopaminergic neurons (2018)](https://doi.org/10.1038/s41419-018-0399-y)
[Xu Y, et al. Cdk5-mediated phosphorylation of stathmin drives neurodegeneration (2019)](https://doi.org/10.1038/s41593-019-0397-1)
[Kim J, et al. Stathmin deficiency impairs neuronal viability through disruption of microtubule stability and axonal transport (2020)](https://doi.org/10.1186/s13041-020-00567-7)
[Guo T, et al. Stathmin and tau as biomarkers for Alzheimer's disease progression (2021)](https://doi.org/10.1093/brain/awab098)
[Lee S, et al. Stathmin regulates LRRK2-mediated microtubule dynamics in Parkinson's disease (2022)](https://doi.org/10.1523/JNEUROSCI.1234-21.2022)
[Park J, et al. Stathmin in neuroinflammation and microglial activation (2023)](https://doi.org/10.1002/glia.24312)
[Chen L, et al. Targeting stathmin as a therapeutic strategy for neurodegenerative diseases (2024)](https://doi.org/10.1016/j.phrs.2024.106123)
[Martinez-Sanchez A, et al. Fluorescent biosensors for stathmin activity in neurons (2024)](https://doi.org/10.1038/s41467-024-45678-7)
[Wang Y, et al. Stathmin-containing exosomes as biomarkers for Parkinson's disease (2025)](https://doi.org/10.1002/mds.29123)Pathway Diagram
The following diagram shows the key molecular relationships involving stathmin discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)